SARS-COV-2 Infection, Vaccination, and Immune-Mediated Diseases: Results of a Single-Center Retrospective Study.
COVID-19
Immuno-Mediated Reactions
SARS-CoV2
autoimmunity
vaccine
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2022
2022
Historique:
received:
21
01
2022
accepted:
28
02
2022
entrez:
7
4
2022
pubmed:
8
4
2022
medline:
9
4
2022
Statut:
epublish
Résumé
The relationship between infections or vaccine antigens and exacerbations or new onset of immune-mediated diseases (IMDs) has long been known. In this observational study, conducted during the COVID-19 pandemic, we evaluated the onset of clinical and laboratory immune manifestations related to COVID-19 or SARS-CoV-2 vaccination. Four groups of patients were evaluated: A) 584 COVID-19 inpatients hospitalized from March 2020 to June 2020 and from November 2020 to May 2021; B) 135 outpatients with previous SARS-CoV-2 infection, assessed within 6 months of recovery; C) outpatients with IMDs in remission and flared after SARS-COV-2 infection; D) outpatients with symptoms of probable immune-mediated origin after SARS-CoV-2 vaccination. In cohort A we observed n. 28 (4.8%) arthralgia/myalgia, n. 2 (0.3%) arthritis, n. 3 (0.5%) pericarditis, n. 1 (0.2%) myocarditis, n. 11 (1.9%) thrombocytopenia or pancytopenia, and in the follow up cohort B we identified 9 (6.7%) cases of newly diagnosed IMDs after the recovery from COVID-19. In all cases, serological alterations were not observed.In cohort C we observed n.5 flares of pre-existing IMD after SARS-COV2 infection, and in the cohort D n. 13 IMD temporally close with SARS-CoV-2 vaccination in 8 healthy subjects (with clinical classifiable IMD-like presentation) and in 5 patients affected by an anamnestic IMD. Also in these latter cases, except in 2 healthy subjects, there were not found serological alterations specific of a classifiable IMD. This study suggests that the interplay between SARS-CoV-2 and the host may induce complex immune-mediated reactions, probably induced by the anti-spike antibodies, in healthy people and IMD patients without specific serological autoimmunity. Moreover, our data suggest that the anti-SARS-CoV-2 antibodies generated by the vaccination may cause in healthy subjects' clinical manifestations similar to well-definite IMDs. These findings support the hypothesis that SARS-Cov2 infection in COVID-19 induce an innate and adaptive immune response that may be both responsible of the symptoms correlated with the occurrence of the IMDs described in our study. And, in this context, the IMDs observed in healthy people in close temporal correlation with the vaccination suggest that the anti-Spike antibodies may play a key role in the induction of an abnormal and deregulated immune response.
Identifiants
pubmed: 35386714
doi: 10.3389/fimmu.2022.859550
pmc: PMC8977466
doi:
Substances chimiques
COVID-19 Vaccines
0
RNA, Viral
0
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
859550Informations de copyright
Copyright © 2022 Luchetti Gentiloni, Paci, Marconi, Gigli, Benfaremo, Sordillo, Macchini, Massaccesi, Perna, Offidani and Moroncini.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Ann Rheum Dis. 2021 Jan;80(1):88-95
pubmed: 32978237
J Rheumatol Suppl. 2010 May;85:2-10
pubmed: 20436161
Lancet Rheumatol. 2020 Sep;2(9):e518-e519
pubmed: 32838313
Nat Med. 2021 May;27(5):759-761
pubmed: 33972793
Diabetes Res Clin Pract. 2020 Jun;164:108166
pubmed: 32339533
J Clin Invest. 2021 Dec 15;131(24):
pubmed: 34710063
SN Compr Clin Med. 2020;2(11):2048-2058
pubmed: 32984764
Lancet Rheumatol. 2021 Jul;3(7):e469-e470
pubmed: 33817664
Nature. 2021 Feb;590(7844):29-31
pubmed: 33469204
Int Immunopharmacol. 2021 Oct;99:107970
pubmed: 34280851
Rheumatol Int. 2021 Mar;41(3):509-518
pubmed: 33515320
Ann Rheum Dis. 2022 Apr;81(4):564-568
pubmed: 34686479
J Autoimmun. 2020 Nov;114:102506
pubmed: 32563547
Ann Rheum Dis. 2021 Oct;80(10):1352-1354
pubmed: 34158370
J Med Virol. 2022 Jan;94(1):54-62
pubmed: 34427929
Clin Immunol. 2021 Mar;224:108665
pubmed: 33429060
Scand J Immunol. 2021 Nov;94(5):e13101
pubmed: 34940980
Front Immunol. 2021 Apr 15;12:635018
pubmed: 33936047
Ann Rheum Dis. 2020 Aug 4;:
pubmed: 32753423
Am J Manag Care. 2002 Dec;8(21 Suppl):S664-81; quiz S682-5
pubmed: 12516953
Arthritis Rheumatol. 2022 Jan;74(1):28-32
pubmed: 34346185
Vaccines (Basel). 2021 Apr 29;9(5):
pubmed: 33946748
N Engl J Med. 2020 Jul 23;383(4):347-358
pubmed: 32598830
Vaccines (Basel). 2021 Dec 02;9(12):
pubmed: 34960174
Ann Rheum Dis. 1999 Aug;58(8):454-61
pubmed: 10419862
Cell Mol Immunol. 2018 Jun;15(6):586-594
pubmed: 29503439
Clin Exp Rheumatol. 2013 Mar-Apr;31(2 Suppl 76):3-7
pubmed: 23910606
Ann Rheum Dis. 2022 Mar;81(3):440-441
pubmed: 34836886
Clin Immunol. 2020 Aug;217:108480
pubmed: 32461193